These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 29614779)

  • 41. Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1.
    Shangguan S; Ehrenberg PK; Geretz A; Yum L; Kundu G; May K; Fourati S; Nganou-Makamdop K; Williams LD; Sawant S; Lewitus E; Pitisuttithum P; Nitayaphan S; Chariyalertsak S; Rerks-Ngarm S; Rolland M; Douek DC; Gilbert P; Tomaras GD; Michael NL; Vasan S; Thomas R
    Elife; 2021 Sep; 10():. PubMed ID: 34533134
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses.
    Beltran-Pavez C; Bontjer I; Gonzalez N; Pernas M; Merino-Mansilla A; Olvera A; Miro JM; Brander C; Alcami J; Sanders RW; Sanchez-Merino V; Yuste E
    J Virol; 2022 Jan; 96(1):e0134321. PubMed ID: 34668778
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adjuvants: tailoring humoral immune responses.
    McElrath MJ
    Curr Opin HIV AIDS; 2017 May; 12(3):278-284. PubMed ID: 28257301
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HIV-1 phylogenetics and vaccines.
    Rolland M
    Curr Opin HIV AIDS; 2019 May; 14(3):227-232. PubMed ID: 30925535
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects.
    Gach JS; Gorlani A; Dotsey EY; Becerra JC; Anderson CT; Berzins B; Felgner PL; Forthal DN; Deeks SG; Wilkin TJ; Casazza JP; Koup RA; Katlama C; Autran B; Murphy RL; Achenbach CJ
    PLoS One; 2016; 11(8):e0160341. PubMed ID: 27500639
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HIV Vaccines: One Step Closer.
    Low MSY; Tarlinton D
    Trends Mol Med; 2017 Jan; 23(1):1-3. PubMed ID: 27889424
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rational antibody-based HIV-1 vaccine design: current approaches and future directions.
    Walker LM; Burton DR
    Curr Opin Immunol; 2010 Jun; 22(3):358-66. PubMed ID: 20299194
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Induction of Identical IgG HIV-1 Envelope Epitope Recognition Patterns After Initial HIVIS-DNA/MVA-CMDR Immunization and a Late MVA-CMDR Boost.
    Joachim A; Ahmed MIM; Pollakis G; Rogers L; Hoffmann VS; Munseri P; Aboud S; Lyamuya EF; Bakari M; Robb ML; Wahren B; Sandstrom E; Nilsson C; Biberfeld G; Geldmacher C; Held K
    Front Immunol; 2020; 11():719. PubMed ID: 32411138
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
    Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HIV-Host Interactions: Implications for Vaccine Design.
    Haynes BF; Shaw GM; Korber B; Kelsoe G; Sodroski J; Hahn BH; Borrow P; McMichael AJ
    Cell Host Microbe; 2016 Mar; 19(3):292-303. PubMed ID: 26922989
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Designing boosting immunogens for HIV-1 vaccine development.
    Liu Q
    Cell Host Microbe; 2024 May; 32(5):632-634. PubMed ID: 38723601
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses.
    Ringel O; Vieillard V; Debré P; Eichler J; Büning H; Dietrich U
    Viruses; 2018 Apr; 10(4):. PubMed ID: 29662026
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.
    Sliepen K; Sanders RW
    Expert Rev Vaccines; 2016; 15(3):349-65. PubMed ID: 26654478
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Is developing an HIV-1 vaccine possible?
    Haynes BF; Liao HX; Tomaras GD
    Curr Opin HIV AIDS; 2010 Sep; 5(5):362-7. PubMed ID: 20978375
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A tale of four studies: HIV vaccine immunogenicity and efficacy in clinical trials.
    Zolla-Pazner S; Michael NL; Kim JH
    Lancet HIV; 2021 Jul; 8(7):e449-e452. PubMed ID: 34029515
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Complex immune correlates of protection in HIV-1 vaccine efficacy trials.
    Tomaras GD; Plotkin SA
    Immunol Rev; 2017 Jan; 275(1):245-261. PubMed ID: 28133811
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial.
    Rerks-Ngarm S; Pitisuttithum P; Excler JL; Nitayaphan S; Kaewkungwal J; Premsri N; Kunasol P; Karasavvas N; Schuetz A; Ngauy V; Sinangil F; Dawson P; deCamp AC; Phogat S; Garunathan S; Tartaglia J; DiazGranados C; Ratto-Kim S; Pegu P; Eller M; Karnasuta C; Montefiori DC; Sawant S; Vandergrift N; Wills S; Tomaras GD; Robb ML; Michael NL; Kim JH; Vasan S; O'Connell RJ;
    J Infect Dis; 2017 Apr; 215(8):1255-1263. PubMed ID: 28329190
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.
    Belshe RB; Graham BS; Keefer MC; Gorse GJ; Wright P; Dolin R; Matthews T; Weinhold K; Bolognesi DP; Sposto R
    JAMA; 1994 Aug; 272(6):475-80. PubMed ID: 7913731
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Support for the RV144 HIV vaccine trial.
    Belshe R; Franchini G; Girard MP; Gotch F; Kaleebu P; Marthas ML; McChesney MB; McCullough R; Mhalu F; Salmon-Ceron D; Sekaly RP; van Rompay K; Verrier B; Wahren B; Weissenbacher M
    Science; 2004 Jul; 305(5681):177-80; author reply 177-80. PubMed ID: 15247455
    [No Abstract]   [Full Text] [Related]  

  • 60. Role of humoral immunity in host defense against HIV.
    Baum LL
    Curr HIV/AIDS Rep; 2010 Feb; 7(1):11-8. PubMed ID: 20425053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.